A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-03-18
Adverse events
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-05-28 (study day 52); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-06-21 (study day 76); relationship: N
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-10 (study day 279); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-05-30 (study day 420); relationship: not assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-07-12 (study day 463); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-09-11 (study day 524); relationship: N
Data queries
No data queries.